SEC Form 4 · accession 0001209191-16-122762
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lauren P Silvernail
Officer — CFO, CBO & Secretary
Period of report
May 19, 2016
Accepted (ET)
May 23, 2016 · 8:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 19, 2016 | F | 1,753 | $17.11 | D | 29,942 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents 1,753 shares withheld by and surrendered to the Issuer on May 19, 2016 to satisfy tax withholding obligations that arose in connection with the vesting of 4,667 shares of restricted stock.